» Articles » PMID: 27347881

Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis

Overview
Journal PLoS One
Date 2016 Jun 28
PMID 27347881
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: There were no reports on predicting long-term efficacy of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). This study aimed to detect short-term changes of cytokines and C-reactive protein (CRP) in patients with UC undergoing FMT, and to evaluate the predictive value of CRP and cytokines for the long-term efficacy of FMT.

Methods: Nineteen patients with moderate to severe UC (Mayo score ≥ 6) were treated with single fresh FMT through mid-gut. Serum samples were collected before and three days post-FMT. Clinical responses were evaluated by a minimum follow-up of three months. Patients with clinical improvement and remission at the assessment point of three-month were included as response group, while patients without clinical improvement or remission were included as non-response group. Serum concentrations of cytokines (IL-1β, IL-2, IL-4, IL-6, IL-10, IL-11, IL-17A, IFN-γ, TNF, TNFR-1, TNFR-2, MCP-1, G-CSF, GM-CSF) and CRP were assayed to predict the clinical response of FMT.

Results: In total, 10.5% (2/19) of patients achieved clinical remission and 47.4% (9/19) achieved clinical improvement (Response group, including clinical remission and clinical improvement), 42.1% (8/19) failed to benefit from FMT (Non-response group). In both Response group and Non-response group, the level of CRP at three days after FMT didn't show significant decrease compared with that before FMT (p>0.05). However, in Response group, CRP level at three months after FMT decreased significantly than that before FMT (p<0.05). Compared with healthy controls (n = 9), patients with UC showed a higher baseline level of serum IL-6, TNFR-2 and G-CSF, and a lower level of IL-2 and IL-4 (p<0.05). In both Response group and Non-response group, none of the eleven detectable cytokines showed a significant difference between the value at three days after FMT and that before FMT (p>0.05).

Conclusions: Patients with moderate to severe UC presented a complex disorder of cytokines. However, the efficacy of FMT for UC might not be predicted by the short-term surveillance of cytokines and CRP.

Citing Articles

A predictive machine-learning model for clinical decision-making in washed microbiota transplantation on ulcerative colitis.

Zhang S, Lu G, Wang W, Li Q, Wang R, Zhang Z Comput Struct Biotechnol J. 2024; 24:583-592.

PMID: 39281978 PMC: 11399476. DOI: 10.1016/j.csbj.2024.08.021.


The Impact of Microbiome Interventions on the Progression and Severity of Inflammatory Bowel Disease: A Systematic Review.

Kasapoglu M, Yadavalli R, Nawaz S, Althwanay A, AlEdani E, Kaur H Cureus. 2024; 16(5):e60786.

PMID: 38779440 PMC: 11110475. DOI: 10.7759/cureus.60786.


Safety profile and effects on the peripheral immune response of fecal microbiota transplantation in clinically healthy dogs.

Lee M, Questa M, Wanakumjorn P, Kol A, McLaughlin B, Weimer B J Vet Intern Med. 2024; 38(3):1425-1436.

PMID: 38613431 PMC: 11099722. DOI: 10.1111/jvim.17061.


Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial.

Kragsnaes M, Jensen J, Nilsson A, Malik M, Munk H, Pedersen J RMD Open. 2024; 10(1).

PMID: 38296309 PMC: 10836383. DOI: 10.1136/rmdopen-2023-003750.


The Role of the Microbiome in the Pathogenesis and Treatment of Ulcerative Colitis-A Literature Review.

Swirkosz G, Szczygiel A, Logon K, Wrzesniewska M, Gomulka K Biomedicines. 2023; 11(12).

PMID: 38137365 PMC: 10740415. DOI: 10.3390/biomedicines11123144.


References
1.
Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P . Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2014; 30(1):51-8. DOI: 10.1111/jgh.12727. View

2.
Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R . Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res. 2014; 63(11):943-50. DOI: 10.1007/s00011-014-0768-7. View

3.
Bennet J, Brinkman M . Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989; 1(8630):164. DOI: 10.1016/s0140-6736(89)91183-5. View

4.
Liu L, Guo Z, Lv Z, Sun Y, Cao W, Zhang R . The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. Int Immunopharmacol. 2008; 8(11):1481-92. DOI: 10.1016/j.intimp.2008.04.013. View

5.
Babickova J, Gardlik R . Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol. 2015; 21(40):11321-30. PMC: 4616208. DOI: 10.3748/wjg.v21.i40.11321. View